ARCHIVES

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

This article is from The Cancer Letter archive.

Vol. 32 No. 31 | September 8, 2006

Download PDF Visit The Full Archive

Related Articles

AACR Changes Its Logo— For The Fifth Time Since 2000

July 11, 2014

Preoperative Chemo Doubles Survival In Locally Advanced Bladder Cancer

May 25, 2001

Book For Survivors, Other New Publications

August 23, 1991

Clinical Trials Approved In August 2002 By NCI

September 27, 2002

FDA Approves Gleevec For First Line Rx Of CML

January 31, 2003

Edelson to Direct Yale Cancer Center (12-page issue).

May 30, 2003